Blar i Institutt for klinisk og molekylær medisin på tidsskrift "Cancer Medicine"

Viser treff 1-3 av 3

    • Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma 

      Lund, Johan; Gruber, Astrid; Lauri, Birgitta; Duru, Adil Doganay; Blimark, Cecilie; Swedin, Agneta; Hansson, Markus; Forsberg, Karin; Ahlberg, Lucia; Carlsson, Conny; Waage, Anders; Gimsing, Peter; Vangsted, Annette Juul; Frølund, Ulf; Holmberg, Erik; Gahrton, Gösta C.A.; Alici, Evren; Hardling, Mats; Mellqvist, Ulf-Henrik; Nahi, Hareth (Journal article; Peer reviewed, 2018)
      Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once ...

    • MRI-based radiomic signatures for pretreatment prognostication in cervical cancer 

      Wagner-Larsen, Kari Strøno; Hodneland, Erlend; Fasmer, Kristine Eldevik; Lura, Njål; Woie, Kathrine; Bertelsen, Bjørn; Salvesen, Øyvind Olav; Halle, Mari Kyllesø; Smit, Noeska Natasja; Krakstad, Camilla; Haldorsen, Ingfrid S. (Peer reviewed; Journal article, 2023)
      Background Accurate pretherapeutic prognostication is important for tailoring treatment in cervical cancer (CC). Purpose To investigate whether pretreatment MRI-based radiomic signatures predict disease-specific ...

    • Targeted next-generation sequencing of 22 mismatch repair genes identifies Lynch syndrome families 

      Talseth-Palmer, Bente; Bauer, Denis; Sjursen, Wenche; Evans, Tiffany-Jane; McPhillips, Mary; Proietto, Anthony; Otten, Geoffrey; Spigelman, Allan D.; Scott, Rodney J. (Peer reviewed; Journal article, 2016)
      Causative germline mutations in mismatch repair (MMR ) genes can only be identified in ~50% of families with a clinical diagnosis of the inherited colorectal cancer (CRC ) syndrome hereditary nonpolyposis colorectal cancer ...